Volume | 1 |
|
|||||
News | - | ||||||
Day High | Low High |
||||||
Day Low |
Company Name | Stock Ticker Symbol | Market | Type |
---|---|---|---|
Xencor Inc | XNCR | NASDAQ | Common Stock |
Open Price | Low Price | High Price | Close Price | Prev Close |
---|---|---|---|---|
22.42 |
Trades | Volume | Avg Volume | 52 Week Range |
---|---|---|---|
1 | 1 | - | 16.49 - 30.21 |
Last Trade Time | Type | Quantity | Stock Price | Currency |
---|---|---|---|---|
08:18:35 | 1 | $ 22.42 | USD |
Xencor Inc Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
1.37B | 61.12M | - | 168.34M | -126.09M | -2.06 | - |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | - | - | - |
Xencor News
Loading Messages....
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical XNCR Price Data
Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 22.81 | 23.52 | 21.34 | 22.25 | 417,321 | -0.39 | -1.71% |
1 Month | 23.40 | 24.45 | 21.34 | 23.03 | 767,815 | -0.98 | -4.19% |
3 Months | 22.06 | 26.84 | 18.26 | 21.97 | 726,522 | 0.36 | 1.63% |
6 Months | 20.57 | 26.84 | 16.49 | 20.90 | 601,775 | 1.85 | 8.99% |
1 Year | 27.97 | 30.21 | 16.49 | 22.30 | 452,278 | -5.55 | -19.84% |
3 Years | 41.67 | 45.365 | 16.49 | 27.35 | 354,139 | -19.25 | -46.20% |
5 Years | 32.04 | 58.345 | 16.49 | 31.14 | 354,607 | -9.62 | -30.02% |
Xencor Description
Xencor Inc is a clinical-stage biopharmaceutical company based in the United States. It focuses on discovering and developing engineered monoclonal antibody and other protein therapeutics to treat severe and life-threatening diseases with unmet medical needs. The company uses its XmAb technology platform to create antibody product candidates such as XmAb5871 and XmAb7195. It also has a few pre-clinical stage candidates in its portfolio such as XmAb14045 and XmAb13676. It earns its revenue from research and development collaborations and licenses of its internally developed drug candidates. |